INNATE PHARMA (EPA:IPH) Half-year report on Innate Pharma's liquidity contract with Natixis Securities

Transparency directive : regulatory news

18/07/2011 17:48

PRESS RELEASE

HALF-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT WITH NATIXIS SECURITIES

Marseilles, France, July 18, 2011

Under the liquidity contract entrusted by Innate Pharma to Natixis Securities,
the following assets appeared on the liquidity account as at June 30, 2011:

     121,882 shares of Innate Pharma, and
     33,311.37 euros in cash.

For information, the following assets appeared on the liquidity account at the
latest report:

     133,129 shares of Innate Pharma, and
     10,378.28 euros in cash.

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by license agreements with
Novo Nordisk A/S and Bristol Myers Squibb, two major pharmaceutical companies.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 85 employees as at March 31, 2011.

Learn more about Innate Pharma at www.innate-pharma.com. Practical Information
about Innate Pharma shares:

ISIN code     FR0010331421
Ticker code   IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                     Alize Public Relations
Laure-Hélène Mercier              Caroline Carmagnol
Director, Investor Relations      Phone: +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87       Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com       caroline@alizerp.com

110718 Half-year report on liquidity agreement

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Half-year report on Innate Pharma's liquidity contract with Natixis Securities

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories